1. Home
  2. CTRM vs DARE Comparison

CTRM vs DARE Comparison

Compare CTRM & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castor Maritime Inc.

CTRM

Castor Maritime Inc.

HOLD

Current Price

$2.20

Market Cap

21.1M

ML Signal

HOLD

Logo Dare Bioscience Inc.

DARE

Dare Bioscience Inc.

HOLD

Current Price

$1.67

Market Cap

24.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTRM
DARE
Founded
2016
2015
Country
Cyprus
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.1M
24.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CTRM
DARE
Price
$2.20
$1.67
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
81.2K
73.2K
Earning Date
12-03-2025
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$75,412,579.00
N/A
Revenue This Year
N/A
$3,843.33
Revenue Next Year
N/A
$8,700.33
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.84
$1.61
52 Week High
$2.92
$9.19

Technical Indicators

Market Signals
Indicator
CTRM
DARE
Relative Strength Index (RSI) 50.50 34.26
Support Level $2.12 $1.68
Resistance Level $2.39 $1.75
Average True Range (ATR) 0.15 0.07
MACD -0.01 -0.01
Stochastic Oscillator 23.56 0.00

Price Performance

Historical Comparison
CTRM
DARE

About CTRM Castor Maritime Inc.

Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments namely (i) the dry bulk segment (ii) the containership segment and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.

About DARE Dare Bioscience Inc.

Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

Share on Social Networks: